See the DrugPatentWatch profile for Jornay
Jornay is a brand-name prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in individuals aged 6 and older [1]. It is designed to provide a controlled release of its active ingredient, methylphenidate, throughout the day [1][2].
How does Jornay work for ADHD?
Jornay's mechanism of action involves the release of methylphenidate, a central nervous system stimulant. Methylphenidate works by increasing the levels of dopamine and norepinephrine in the brain [1]. These neurotransmitters are believed to play a crucial role in attention, focus, and impulse control. Jornay utilizes a multi-time-release capsule system that delivers methylphenidate at three distinct times: upon waking, six hours later, and then again eight hours after that [2]. This staggered release aims to manage ADHD symptoms from morning until night [1][2].
What is the active ingredient in Jornay?
The active ingredient in Jornay is methylphenidate hydrochloride [1].
Who manufactures Jornay?
Jornay is manufactured by Ironshore Pharmaceuticals [3].
When does Jornay's patent expire?
Information on specific patent expiry dates for Jornay can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [4].
What are the potential side effects of Jornay?
Common side effects associated with Jornay may include decreased appetite, insomnia, weight loss, anxiety, irritability, nausea, vomiting, and dizziness [1]. Serious side effects can include psychiatric problems such as new or worsening behavior and thought problems, or circulation problems in the fingers and toes [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How does Jornay compare to other ADHD medications?
Jornay is a methylphenidate-based stimulant, placing it in the same drug class as medications like Ritalin and Concerta. However, its unique multi-time-release formulation differentiates it by aiming for continuous symptom coverage from morning to evening [2]. Other ADHD medications may use different release mechanisms or contain different active ingredients, such as amphetamines (e.g., Adderall) or non-stimulants (e.g., Strattera) [1]. The choice of medication often depends on individual patient needs, symptom profiles, and tolerance [1].
What clinical data supports Jornay's effectiveness?
Clinical trials have demonstrated that Jornay is effective in reducing ADHD symptoms in children, adolescents, and adults [1]. These studies typically measure symptom reduction using standardized rating scales for ADHD.
Are there any contraindications for Jornay?
Jornay is contraindicated in patients with certain pre-existing conditions, including hypersensitivity to methylphenidate or other components of the medication, and in individuals who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days [1].
What are the risks associated with stimulant medications like Jornay?
Like other central nervous system stimulants, Jornay carries potential risks. These include the possibility of abuse, dependence, and diversion. Cardiovascular risks, such as elevated blood pressure and heart rate, can also occur. Additionally, there is a risk of sudden death in individuals with pre-existing structural cardiac abnormalities or other serious heart problems [1].
Where can I find more information on Jornay patents and exclusivity?
Detailed information regarding Jornay's patent status, including expiry dates and any related litigation or exclusivity periods, is available through specialized databases such as DrugPatentWatch.com [4].
What are the concerns of patients regarding Jornay treatment?
Patients and caregivers often have concerns related to managing potential side effects like appetite suppression and sleep disturbances, ensuring consistent medication adherence due to the specific dosing schedule, and understanding the long-term effects and safety profile of stimulant treatment [1].
---
1. Jornay PMD Prescribing Information.
2. Ironshore Pharmaceuticals. Jornay® (methylphenidate hydrochloride) Extended-Release Capsules.
3. Ironshore Pharmaceuticals. About Ironshore.
4. DrugPatentWatch.com.